RxDoctor Payments Data

Meghan Garstka, MD

Surgical Oncology · Baltimore, MDNPI 1154764421

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 2 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Johnson & Johnson accounts for 77.8% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for surgical oncology clinicians in MD, where the typical reported total is $299.

$86in general payments, 2019–2025

Across 2 payments — averaging $42.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$67
  • Intuitive Surgical$19
$262,518in research payments, 2019–2025

Across 4 payments — averaging $65,630 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$263K

What the payments were for

  • Food & beverage$86100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson1$67
Intuitive Surgical1$19

How this compares

$86 in reported general payments places this provider in the 15th percentile of 40 surgical oncology providers in Maryland.

See all surgical oncology providers in Maryland

Medicare billing

Part B allowed, 2024
$113,068
Medicare patients
138
Services billed
398

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone Hcl34$82

Paid to pharmacies, not to this prescriber.

Other surgical oncology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →